Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.

"Potential conflicts of interest. B. W. T. has been on the advisory board for Moderna, Takeda, and CSL-Behring; has received research funding from MSD and Seqirus; and has received honoraria from Pfizer, Alexion, and Janssen that were paid to his institution. M. A. S. has served on data safety monitoring and adjudication committees or advisory committees for Gilead Sciences, F2G, Cidara, Takeda, Merck, Roche, and Pfizer, and has received research funding from Gilead Sciences, Merck, and F2G. J. F. S. has served on the advisory board for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Roche, and Janssen; served on a scientific advisory board for Genor Biopharma; has received research funding from AbbVie, BMS, and Roche; has served on speakers’ bureaus for AbbVie, BMS, and Roche; and is a consultant and has given expert testimony to TG Therapeutics. T. S. has received compensation for serving on scientific advisory boards, honoraria for consultancy, and funding for travel from Biogen. All other authors report no potential conflicts."

"Financial support. This project has received funding from a VC 2 Research Grant (V. G. H.). V. G. H. is supported by a National Health and Medical Research Council (NHMRC) postgraduate PhD scholarship (award number 2014210). D. A. W. is funded by an NHMRC Investigator Grant (grant number APP1174555). B. W. T. is supported by the Australian government Medical Research Future Fund (MRFF) Investigator Fellowship (EL-2, award number 1195894). This work was supported by the NHMRC Leadership Investigator Grant to K. K. (grant number 1173871); an NHMRC Emerging Leadership Level 1 Investigator Grant to T. H. O. N. (grant number 1194036); and MRFF Award (award number 2016062) to K. K., T. H. O. N., L. C. R., and B. W. T. Financial support."